Remove 2011 Remove Patients Remove Pharmaceutical manufacturing
article thumbnail

A Powerful Point-of-Sale Partnership that Delivers on the Promise of Affordable Insulin

PM360

This collaboration builds on Sanofi’s recent announcement to lower the list price for Lantus and cap OOP costs at $35 for all patients with commercial insurance, which goes into effect January 1, 2024. The price is available to cash-paying patients with a valid prescription. for only $35. Currently, an estimated 37.3 of the U.S.

Retail 52
article thumbnail

Strengthening and transforming the pharmaceutical supply chain

European Pharmaceutical Review

Manufacturing delays and capacity issues that continue to impact the pharmaceutical supply chain have led to medicine shortages around the globe; an issue that has been exacerbated further by geopolitical events, the energy crisis and rising inflation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Everything You Need to Know About Market Access in China

PM360

In 2021, a consensus was reached that classified rare diseases as those with an incidence of less than 1 in 10,000 newborns, or a prevalence of less than 1 in 10,000 adults, or a patient population of less than 140,000 in total. The GBA gives patients access to innovative drugs (e.g.,

Marketing 105
article thumbnail

Tracking the Drug Trail

Pharmaceutical Technology

Pharmaceutical companies, regulatory agencies and governments are becoming increasingly concerned about fraud and counterfeiting throughout the pharmaceutical supply chain, especially with the cost of drugs going up. Europe is favouring 2D data matrix codes to encode information while the US is tending more towards RFID. .